var data={"title":"Histrelin: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Histrelin: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6315?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=histrelin-drug-information\" class=\"drug drug_general\">see &quot;Histrelin: Drug information&quot;</a> and <a href=\"topic.htm?path=histrelin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Histrelin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179193\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Supprelin LA;</li>\n      <li>Vantas</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2934287\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Vantas</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1017783\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Gonadotropin Releasing Hormone Agonist</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1017815\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=histrelin-drug-information\" class=\"drug drug_general\">see &quot;Histrelin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Central precocious puberty:</b> Children &ge;2 years: Supprelin LA: SubQ: 50 mg implant surgically inserted every 12 months; discontinue at the appropriate time for the onset of puberty</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Prostate cancer, advanced:</b> Vantas: SubQ: 50 mg implant surgically inserted every 12 months</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Supprelin LA: Children &ge;2 years: There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Vantas: Adults: CrCl &ge;15 mL/minute: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> All patients: There are no dosage adjustments provided in manufacturer's labeling; has not been adequately studied.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179173\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Subcutaneous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Supprelin LA: 50 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vantas: 50 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179161\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50133910\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information, and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Supprelin LA <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022058s014s015lbl.pdf#page=19&amp;token=XpnPwCrTT6lhacUEfwI0dFfs0LmHR9LKK9W5Ty130UeMPKko0wh2RL0qSPBP9SHEAqtl8FysiTBc6GuXKgOGUxdAh9xCLgZwTDkwSqPTVLenHLw8iIndZdqi16fPSug4&amp;TOPIC_ID=87619\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022058s014s015lbl.pdf#page=19</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1017819\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;\">SubQ: Surgical implantation within a sterile field using provided implantation device is required. Insert into the inner portion of the upper arm; it is preferable to use the patient's nondominant arm for placement; implant should be placed halfway between the shoulder and the elbow at the crease between the tricep and the bicep. Implant removal should occur after ~12 months; a replacement implant may be inserted if therapy is to be continued. For removal, palpate area of incision to locate implant; if not readily palpated, ultrasound, CT, or MRI may be necessary to locate implant; plain films are not recommended because the implant is not radiopaque. Refer to manufacturer's labeling for full insertion and removal details.  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132616\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and (when dosage form allows) closed system transfer devices (CSTDs) for compounding. Double gloving and a protective gown are recommended during administration (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179190\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Upon delivery, separate contents of implant carton. Store implant (small carton containing amber plastic pouch and glass vial) under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) until the day of insertion; excursions permitted to 25&deg;C (77&deg;F) for 7 days (if unused within 7 days, may return to proper refrigeration until product expiration date). Keep implant wrapped in the amber pouch for protection from light; do not freeze. Do not open implant vial until just before the time of insertion. The implantation insertion kit should be stored at room temperature (do not refrigerate insertion kit).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1017784\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Supprelin LA: Treatment of central precocious puberty (CPP) (FDA approved in children ages &ge;2 years)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vantas: Palliative treatment of advanced prostate cancer (FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179214\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>CPP:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Emotional lability, headache, migraine, sensation of cold</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Dermatological reaction (insertion site reaction includes bruise, discomfort, erythema, pain, protrusion of implant area, pruritus, soreness, swelling, tingling). scarring, pruritus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Altered hormone levels. gynecomastia, hypermenorrhea, weight gain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Breast tenderness, dysmenorrhea, precocious puberty (progression of central precocious puberty), uterine hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Pituitary neoplasm</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Localized infection (implant site)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Application site pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Keloid-like scar</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Epistaxis, flu-like symptoms</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Postoperative pain, procedural complications (suture-related)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Aggressive behavior, amblyopia, crying, device expulsion, hostility, irritability, seizure, suicidal ideation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prostate cancer:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Dermatological reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Flushing, palpitations, peripheral edema, ventricular premature contractions</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Depression, dizziness, fatigue, headache, insomnia, irritability, lethargy, malaise, pain, sensation of cold</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Diaphoresis, genital pruritus, hypotrichosis, night sweats, pruritus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Decreased libido, fluid retention, gynecomastia, hot flash, hypercalcemia, hypercholesterolemia, increased lactate dehydrogenase, increased prostatic acid phosphatase, increased serum glucose, weight gain, weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal distress, constipation, food cravings, increased appetite, nausea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Breast tenderness, dysuria, erectile dysfunction, exacerbation of gynecomastia, exacerbation of hematuria, exacerbation of urinary frequency, hematuria, mastalgia, testicular atrophy (expected pharmacological consequence of testosterone suppression), urinary frequency, urinary retention</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia, bruise, hematoma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatic disease, increased serum AST</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Bruising at injection site, erythema at injection site, inflammation at injection site, injection site infection, pain at injection site, tenderness at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, back pain, exacerbation of back pain, limb pain, muscle twitching, myalgia, neck pain, ostealgia, tremor, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Decreased creatinine clearance, exacerbation of renal failure, nephrolithiasis, renal insufficiency</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Dyspnea on exertion</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Stent occlusion</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Decreased bone mineral density, hepatic injury (severe), increased testosterone level, swelling at injection site</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179179\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to histrelin acetate, gonadotropin-releasing hormone (GnRH), GnRH-agonist analogs, or any component of the formulation; females who are or may become pregnant</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179163\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular effects: Androgen-deprivation therapy (ADT) may increase the risk for cardiovascular disease (Levine 2010). An increased risk of MI, sudden cardiac death, and stroke has been reported with GnRH agonist use in men; monitor for symptoms associated with cardiovascular disease. ADT may prolong the QT/QTc interval; consider the benefits of ADT versus the risk for QT prolongation in patients with a history of QTc prolongation, congenital long QT syndrome, heart failure, frequent electrolyte abnormalities, and in patients with medications known to prolong the QT interval, or with pre-existing cardiac disease. Consider periodic monitoring of electrocardiograms and electrolytes in at-risk patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperglycemia: Hyperglycemia has been reported with androgen deprivation therapy (in prostate cancer) and may manifest as diabetes or worsening of preexisting diabetes. Monitor blood glucose and/or HbA<sub>1c</sub>.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pituitary apoplexy: Rare cases of pituitary apoplexy (frequently secondary to pituitary adenoma) have been observed with GnRH agonist administration (onset from 1 hour to usually &lt;2 weeks); may present as sudden headache, vomiting, visual or mental status changes, and infrequently, cardiovascular collapse; immediate medical attention required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychiatric events: Psychiatric events have been described with GnRH agonists, including histrelin; symptoms of emotional lability, irritability, impatience, anger, and aggression have been reported in postmarketing accounts. Monitor for development or worsening of psychiatric symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: Seizures have been reported in patients receiving GnRH agonists, including histrelin. Reports have occurred in patients with a history of seizures, epilepsy, cerebrovascular disorders, CNS anomalies, or tumors, and patients on concomitant medications associated with seizures (eg, bupropion, SSRIs). Seizures have also been reported in patients without underlying conditions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Spinal cord compression: Has been reported, may contribute to paralysis when used for prostate cancer; closely observe patients with metastatic vertebral lesions for weakness and paresthesias in first few weeks of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tumor flare: Transient increases in serum testosterone (in men with prostate cancer) occur during the first week of use and may result in a worsening of disease signs and symptoms (bone pain, neuropathy, hematuria, ureteral/bladder outlet obstruction, spinal cord compression) during the first week of treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Urinary tract obstruction: Ureteral obstruction may occur when used for prostate cancer; closely observe patients for urinary tract obstruction or poor urine output in first few weeks of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Worsening of symptoms: Transient increases in estradiol serum levels (female) or testosterone levels (female and male) may occur during the first week of use for central precocious puberty (CPP); however, manifestations of puberty should decrease within 4 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Implant complications: Proper surgical insertion technique is essential to avoid complications. Patients should keep arm dry for 24 hours and avoid heavy lifting/strenuous exertion of insertion arm for 7 days after implantation. In prostate cancer studies, the implant was not recovered in a small number of patients. Serum testosterone rose above castrate level and the implant was not palpable or visualized (via ultrasound); it was believed to have been extruded. Some patients had continued testosterone levels below castration level even though the implant was not palpable. If the implant breaks during removal in children with CPP, the remaining pieces should be removed; confirm the removal of the entire implant (refer to manufacturer's instructions for removal procedure).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299447\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179166\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=87619&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Choline C 11: Luteinizing Hormone-Releasing Hormone Analogs may diminish the therapeutic effect of Choline C 11. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corifollitropin Alfa: Luteinizing Hormone-Releasing Hormone Analogs may enhance the therapeutic effect of Corifollitropin Alfa. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indium 111 Capromab Pendetide: Luteinizing Hormone-Releasing Hormone Analogs may diminish the diagnostic effect of Indium 111 Capromab Pendetide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179169\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">X (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179180\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Histrelin is contraindicated for use during pregnancy or in women who may become pregnant. Adverse events were observed in animal reproduction studies. May cause fetal harm or spontaneous abortion if administered during pregnancy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1017821\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central precocious puberty:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer labeling: Luteinizing hormone, follicle-stimulating hormone, estradiol, or testosterone serum concentration (after 1 month then every 6 months); height, bone age (every 6 to 12 months); Tanner staging, monitor for clinical evidence of suppression of CPP manifestations</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Consensus recommendation: Tanner stage and growth (growth velocity, height) every 3 to 6 months and bone age periodically. Routine or random stimulated measurements of gonadotropins or sex steroids may be used, particularly if suboptimal response; however, use of FSH levels not typically used (Carel 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostate cancer: Serum testosterone levels, prostate specific antigen (PSA); bone mineral density; weakness, paresthesias, and urinary tract obstruction (especially during first few weeks of therapy); screen for diabetes; monitor for symptoms associated with cardiovascular disease</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179162\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Potent inhibitor of gonadotropin secretion; continuous administration results in, after an initiation phase, the suppression of luteinizing hormone (LH), follicle-stimulating hormone (FSH), and a subsequent decrease in testosterone and dihydrotestosterone (males) and estrone and estradiol (premenopausal females). Testosterone levels are reduced to castrate levels in males (treated for prostate cancer) within 2 to 4 weeks. Additionally, in patients with CPP, linear growth velocity is slowed (improves chance of attaining predicted adult height). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179178\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Prostate cancer: Chemical castration: Within 2 to 4 weeks; CPP: Progression of sexual development stops and growth is decreased within 1 month</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: 12 months (plus a few additional weeks of histrelin release)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Adults: V<sub>d</sub>: ~58.4 L &plusmn; 7.86 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: Adults: ~70% &plusmn; 9%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic via C-terminal dealkylation and hydrolysis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Adults: SubQ: 92%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Adults: Terminal: ~4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: Adults: 12 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323184\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Supprelin LA Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (1): $35,377.64</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Vantas Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (1): $4,401.94</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4301435\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Vantas (AR, BG, CH, CZ, DE, DK, EE, FI, FR, LT, MY, NO, PL, RO, SE, SG, SI, TH);</li>\n      <li>Vantasse (BE, NL);</li>\n      <li>Vantus (HU)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Carel JC, Eugster EA, Rogol A, et al, &quot;Consensus Statement on the Use of Gonadotropin-Releasing Hormone Analogs in Children,&quot; <i>Pediatrics</i>, 2009, 752-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/histrelin-pediatric-drug-information/abstract-text/19332438/pubmed\" target=\"_blank\" id=\"19332438\">19332438</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eugster EA, Clarke W, Kletter GB, et al, &quot;Efficacy and Safety of Histrelin Subdermal Implant in Children With Central Precocious Puberty: A Multicenter Trial,&quot; <i>J Clin Endocrinol Metab</i>, 2007, 92(5):1697-704.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/histrelin-pediatric-drug-information/abstract-text/17327379/pubmed\" target=\"_blank\" id=\"17327379\">17327379</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levine GN, D&rsquo;Amico AV, Berger P, et al, &ldquo;Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk. A Science Advisory From the American Heart Association, American Cancer Society, and American Urological Association,&rdquo; <i>Circulation</i>, 2010, 121:831-38.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/histrelin-pediatric-drug-information/abstract-text/20124128/pubmed\" target=\"_blank\" id=\"20124128\">20124128</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rahhal S, Clarke WL, Kletter GB, et al, &quot;Results of a Second Year of Therapy With the 12-Month Histrelin Implant for the Treatment of Central Precocious Puberty,&quot; <i>Int J Pediatr Endocrinol</i>, 2009, 2009:812517.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/histrelin-pediatric-drug-information/abstract-text/19956699/pubmed\" target=\"_blank\" id=\"19956699\">19956699</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Supprelin LA (histrelin acetate) [prescribing information]. Malvern, PA: Endo Pharmaceuticals Solutions Inc; May 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vantas (histrelin) [prescribing information]. Malvern, PA: Endo Pharmaceuticals Solutions Inc; June 2017.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 87619 Version 70.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F179193\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F2934287\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1017783\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1017815\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F179173\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F179161\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F50133910\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1017819\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132616\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F179190\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1017784\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F179214\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F179179\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F179163\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299447\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F179166\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F179169\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F179180\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1017821\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F179162\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F179178\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323184\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F4301435\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/87619|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=histrelin-drug-information\" class=\"drug drug_general\">Histrelin: Drug information</a></li><li><a href=\"topic.htm?path=histrelin-patient-drug-information\" class=\"drug drug_patient\">Histrelin: Patient drug information</a></li></ul></div></div>","javascript":null}